KRAS and cancer: Overall, these ratios calculated for the whole group of 19 NSCLC patients (7 KRAS-mutation negative and 12 KRAS-mutation positive) were 18/19 (EBC versus cancer), 10/19 (blood versus cancer) and 9/19 (EBC versus blood), respectively (p = 0.001).